Page 72 - Read Online

Page 10 of 11 Mattana et al. Vessel Plus 2022;6:13 https://dx.doi.org/10.20517/2574-1209.2021.87

Drafting the article and revising it critically for important intellectual content: Mattana F, Muraglia L,
Girardi F, Cerio I, Porcari A, Dore F, Bonfiglioli R, Fanti S
Final approval of the version to be submitted: Mattana F, Muraglia L, Girardi F, Cerio I, Porcari A, Dore F,
Bonfiglioli R, Fanti S

Availability of data and materials
Not applicable.

Financial support and sponsorship
None.

Conflicts of interest
All authors declared that there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2022.

REFERENCES
1. Lane T, Fontana M, Martinez-Naharro A, et al. Natural history, quality of life, and outcome in cardiac transthyretin amyloidosis.
Circulation 2019;140:16-26. DOI PubMed
2. Koike H, Okumura T, Murohara T, Katsuno M. Multidisciplinary approaches for transthyretin amyloidosis. Cardiol Ther 2021. DOI
PubMed PMC
3. Real de Asúa D, Costa R, Galván JM, Filigheddu MT, Trujillo D, Cadiñanos J. Systemic AA amyloidosis: epidemiology, diagnosis,
and management. Clin Epidemiol 2014;6:369-77. DOI PubMed PMC
4. Ansari-Lari MA, Ali SZ. Fine-needle aspiration of abdominal fat pad for amyloid detection: a clinically useful test? Diagn Cytopathol
2004;30:178-81. DOI PubMed
5. Fine NM, Arruda-Olson AM, Dispenzieri A, et al. Yield of noncardiac biopsy for the diagnosis of transthyretin cardiac amyloidosis.
Am J Cardiol 2014;113:1723-7. DOI PubMed
6. Maurer MS. Noninvasive Identification of ATTRwt cardiac amyloid: the re-emergence of nuclear cardiology. Am J Med
2015;128:1275-80. DOI PubMed PMC
7. Gillmore JD, Maurer MS, Falk RH, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation 2016;133:2404-12.
DOI PubMed
8. Falk RH. Diagnosis and management of the cardiac amyloidoses. Circulation 2005;112:2047-60. DOI PubMed
9. Perugini E, Guidalotti PL, Salvi F, et al. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-
propanodicarboxylic acid scintigraphy. J Am Coll Cardiol 2005;46:1076-84. DOI PubMed
10. Stats MA, Stone JR. Varying levels of small microcalcifications and macrophages in ATTR and AL cardiac amyloidosis: implications
for utilizing nuclear medicine studies to subtype amyloidosis. Cardiovasc Pathol 2016;25:413-7. DOI PubMed
11. Puille M, Altland K, Linke RP, et al. 99mTc-DPD scintigraphy in transthyretin-related familial amyloidotic polyneuropathy. Eur J
Nucl Med Mol Imaging 2002;29:376-9. DOI PubMed
12. Rapezzi C, Quarta CC, Guidalotti PL, et al. Role of (99m)Tc-DPD scintigraphy in diagnosis and prognosis of hereditary transthyretin-
related cardiac amyloidosis. JACC Cardiovasc Imaging 2011;4:659-70. DOI PubMed
13. Rapezzi C, Quarta CC, Guidalotti PL, et al. Usefulness and limitations of 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid
scintigraphy in the aetiological diagnosis of amyloidotic cardiomyopathy. Eur J Nucl Med Mol Imaging 2011;38:470-8. DOI PubMed
14. de Haro-del Moral FJ, Sánchez-Lajusticia A, Gómez-Bueno M, García-Pavía P, Salas-Antón C, Segovia-Cubero J. Role of cardiac
99
scintigraphy with mTc-DPD in the differentiation of cardiac amyloidosis subtype. Rev Esp Cardiol (Engl Ed) 2012;65:440-6. DOI
15. Quarta CC, Guidalotti PL, Longhi S, et al. Defining the diagnosis in echocardiographically suspected senile systemic amyloidosis.
JACC Cardiovasc Imaging 2012;5:755-8. DOI PubMed
16. Yamamoto Y, Onoguchi M, Haramoto M, et al. Novel method for quantitative evaluation of cardiac amyloidosis using (201)TlCl and
(99m)Tc-PYP SPECT. Ann Nucl Med 2012;26:634-43. DOI PubMed